Cancer-drug maker Karyopharm Therapeutics filed for Chapter 11 protection on Monday, November 2, and announced a planned merger with Ayrmid through a court-supervised sale process that would allow competing bids. The Newton, Massachusetts-based company said it expects to continue operating in the ordinary course while pursuing a transaction targeted for the first quarter of 2027.
Karyopharm’s announcement says it signed a restructuring support agreement with existing lenders, noteholders and other stakeholders. Ayrmid is the proposed lead bidder, not a buyer that has already completed an acquisition. Karyopharm said it will seek court approval of bidding procedures allowing other parties to submit proposals for its assets.
The company secured commitments from existing secured lenders for up to $55 million in debtor-in-possession financing. Access to that financing requires court approval. The figure is neither a disclosed merger price nor a statement that all $55 million has already been funded. Karyopharm expects approved financing and operating cash generation to support the business and obligations arising after the filing.
The case website maintained by claims agent Stretto confirms November 2 petitions in the U.S. Bankruptcy Court for the Southern District of Texas. It lists Karyopharm Therapeutics under case number 26-90827 and affiliate KPT Texas under 26-90826. The filing begins a legal process; it does not establish that the court has approved the proposed transaction.
Karyopharm said it remains focused on its multiple myeloma and myelofibrosis programs and expects ordinary operations and essential partnerships to continue without interruption. That is the company’s stated plan, not a guarantee that every step of the restructuring will be completed on schedule.
The company markets XPOVIO, or selinexor, in the United States for adults with relapsed or refractory multiple myeloma. Its release also describes work to develop selinexor for myelofibrosis and other hematologic cancers. The bankruptcy announcement is not a new drug approval or a report of new trial results.
Ayrmid is the parent company of Gamida Cell and has commercial operations in the United States, according to the announcement. Its proposed combination with Karyopharm is intended to bring together hematology products and commercial capabilities. Those benefits remain management expectations, subject to a successful transaction and the Chapter 11 process.
For patients and providers, the immediate message is Karyopharm’s intention to maintain the business during restructuring. For investors and creditors, the outcome remains open: the company must obtain court approvals, complete a sale process that permits competing offers and satisfy the conditions of its reorganization plan before the proposed combination can close.
JBizNews Desk | Newton, Massachusetts
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
